tradingkey.logo

Lantheus Holdings Inc

LNTH
57.330USD
-0.800-1.38%
Close 10/28, 16:00ETQuotes delayed by 15 min
3.90BMarket Cap
14.38P/E TTM

Lantheus Holdings Inc

57.330
-0.800-1.38%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Lantheus Holdings Inc

Currency: USD Updated: 2025-10-27

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lantheus Holdings Inc's Score

Industry at a Glance

Industry Ranking
9 / 204
Overall Ranking
43 / 4682
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 13 analysts
Buy
Current Rating
83.385
Target Price
+48.74%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Lantheus Holdings Inc Highlights

StrengthsRisks
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol. It has pre-clinical assets, specifically the TROP2 and DUNP19.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 64.04% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.53B.
Fairly Valued
The company’s latest PE is 14.79, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 80.77M shares, decreasing 7.45% quarter-over-quarter.
Held by Private Capital
Star Investor Private Capital holds 543.64K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.29.

Financial Health

Currency: USD Updated: 2025-10-27

The company's current financial score is 8.93, which is higher than the Healthcare Equipment & Supplies industry's average of 7.47. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 378.05M, representing a year-over-year decrease of 4.07%, while its net profit experienced a year-over-year decrease of 26.87%.

Score

Industry at a Glance

Previous score
8.93
Change
0

Financials

9.84

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

8.36

Operational Efficiency

10.00

Growth Potential

8.88

Shareholder Returns

7.60

Lantheus Holdings Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 8.80, which is higher than the Healthcare Equipment & Supplies industry's average of 7.16. Its current P/E ratio is 14.79, which is 1266.90% below the recent high of 202.19 and 2658.36% above the recent low of -378.42.

Score

Industry at a Glance

Previous score
8.80
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 9/204
No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.72. The average price target for Lantheus Holdings Inc is 80.00, with a high of 130.00 and a low of 60.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts
Buy
Current Rating
83.385
Target Price
+43.45%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

109
Total
7
Median
9
Average
Company name
Ratings
Analysts
Lantheus Holdings Inc
LNTH
13
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 8.89, which is higher than the Healthcare Equipment & Supplies industry's average of 7.16. Sideways: Currently, the stock price is trading between the resistance level at 61.06 and the support level at 52.43, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
8.82
Change
0.07

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(4)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
0.764
Buy
RSI(14)
57.723
Neutral
STOCH(KDJ)(9,3,3)
75.549
Neutral
ATR(14)
1.632
High Vlolatility
CCI(14)
74.473
Neutral
Williams %R
15.866
Overbought
TRIX(12,20)
0.350
Sell
StochRSI(14)
47.053
Neutral
Moving Average
Sell(2)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MA5
57.033
Buy
MA10
56.794
Buy
MA20
54.989
Buy
MA50
54.231
Buy
MA100
63.837
Sell
MA200
77.974
Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.37. The latest institutional shareholding proportion is 118.79%, representing a quarter-over-quarter decrease of 1.72%. The largest institutional shareholder is The Vanguard, holding a total of 6.82M shares, representing 10.03% of shares outstanding, with 4.99% decrease in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
7.50M
-3.78%
Janus Henderson Investors
6.94M
+10.81%
The Vanguard Group, Inc.
Star Investors
6.82M
-2.34%
Fidelity Management & Research Company LLC
4.13M
+90.51%
Farallon Capital Management, L.L.C.
3.32M
-50.67%
State Street Investment Management (US)
2.56M
-2.92%
Geode Capital Management, L.L.C.
1.78M
-0.03%
Wellington Management Company, LLP
1.72M
+89.12%
Westfield Capital Management Company, L.P.
1.50M
-5.92%
T. Rowe Price Investment Management, Inc.
1.43M
+0.99%
1
2

Risk Assessment

Currency: USD Updated: 2025-10-27

The company’s current risk assessment score is 4.86, which is higher than the Healthcare Equipment & Supplies industry's average of 4.64. The company's beta value is 0.03. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.86
Change
0
Beta vs S&P 500 index
0.03
VaR
+4.27%
240-Day Maximum Drawdown
+54.45%
240-Day Volatility
+59.20%

Return

Best Daily Return
60 days
+5.76%
120 days
+5.76%
5 years
+39.12%
Worst Daily Return
60 days
-28.58%
120 days
-28.58%
5 years
-28.58%
Sharpe Ratio
60 days
-0.79
120 days
-1.63
5 years
+0.75

Risk Assessment

Maximum Drawdown
240 days
+54.45%
3 years
+59.46%
5 years
+59.46%
Return-to-Drawdown Ratio
240 days
-0.62
3 years
+0.03
5 years
+0.93
Skewness
240 days
-2.80
3 years
+0.29
5 years
+1.24

Volatility

Realised Volatility
240 days
+59.20%
5 years
+57.12%
Standardised True Range
240 days
+5.80%
5 years
+4.79%
Downside Risk-Adjusted Return
120 days
-143.51%
240 days
-143.51%
Maximum Daily Upside Volatility
60 days
+66.71%
Maximum Daily Downside Volatility
60 days
+72.47%

Liquidity

Average Turnover Rate
60 days
+2.23%
120 days
+1.88%
5 years
--
Turnover Deviation
20 days
+129.43%
60 days
+40.52%
120 days
+18.33%

Peer Comparison

Healthcare Equipment & Supplies
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Boston Scientific Corp
Boston Scientific Corp
BSX
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LivaNova PLC
LIVN
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings Inc
ZBH
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Repligen Corp
Repligen Corp
RGEN
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI